Moderna

Moderna, a US-based pharmaceutical preparation manufacturing company, reported approximately 1.25 billion kg CO2e in total emissions for 2022. This includes approximately 11.89 million kg CO2e from Scope 1 emissions, approximately 225,000 kg CO2e from market-based Scope 2 emissions, and approximately 1.23 billion kg CO2e from Scope 3 emissions. The largest contributors to Scope 3 emissions in 2022 were purchased goods and services, accounting for approximately 1.096 billion kg CO2e, and capital goods, at approximately 86.04 million kg CO2e.

In 2021, Moderna's total emissions were approximately 499.7 million kg CO2e. This comprised approximately 9.36 million kg CO2e from Scope 1, approximately 4,000 kg CO2e from market-based Scope 2, and approximately 490.3 million kg CO2e from Scope 3. Key Scope 3 categories in 2021 included purchased goods and services, at approximately 380.37 million kg CO2e, and capital goods, at approximately 78.62 million kg CO2e.

Moderna has set ambitious climate commitments, including a near-term target to achieve net-zero carbon emissions in Scope 1 and Scope 2 by 2030, originating from their 2023 commitments. They also aim for global net-zero carbon emissions across all scopes by 2030.

The company's Science Based Targets initiative (SBTi) commitments reinforce these goals. Moderna, Inc. commits to reaching net-zero greenhouse gas emissions across its value chain by 2045, from a 2021 base year. Near-term SBTi targets include reducing absolute Scope 1 and Scope 2 GHG emissions by 90% by 2030, from a 2021 base year. For long-term targets, Moderna, Inc. commits to maintaining a minimum of 90% absolute Scope 1 and Scope 2 GHG emissions from 2030 through to 2045. Additionally, they aim to reduce absolute Scope 3 GHG emissions by 90% by 2045 from a 2021 base year. Moderna also commits that 85% of its suppliers, by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2028.